These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29136403)

  • 1. High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
    Lam JUH; Elfström KM; Ejegod DM; Pedersen H; Rygaard C; Rebolj M; Lynge E; Juul KE; Kjær SK; Dillner J; Bonde J
    Br J Cancer; 2018 Jan; 118(1):138-144. PubMed ID: 29136403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.
    Polman NJ; Ebisch RMF; Heideman DAM; Melchers WJG; Bekkers RLM; Molijn AC; Meijer CJLM; Quint WGV; Snijders PJF; Massuger LFAG; van Kemenade FJ; Berkhof J
    Lancet Oncol; 2019 Feb; 20(2):229-238. PubMed ID: 30658933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches.
    Ivanus U; Jerman T; Fokter AR; Takac I; Prevodnik VK; Marcec M; Gajsek US; Pakiz M; Koren J; Celik SH; Kramberger KG; Klopcic U; Kavalar R; Zatler SS; Kuzmanov BG; Florjancic M; Nolde N; Novakovic S; Poljak M; Zakelj MP
    Radiol Oncol; 2018 Sep; 52(4):399-412. PubMed ID: 30216191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A feasibility study on cervical screening in non-attenders invited to undergo HPV self-sampling with cytology triage versus repeat invitation for cytology screening in Hokkaido].
    Taniguchi S; Sakuragi N; Hanley SJB; Tsukiyama K; Fujita H; Sagae S; Kajii N; Watari H; Tamakoshi A
    Nihon Koshu Eisei Zasshi; 2021 Dec; 68(11):719-727. PubMed ID: 34373426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
    Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
    BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    El-Zein M; Bouten S; Louvanto K; Gilbert L; Gotlieb W; Hemmings R; Behr MA; Franco EL;
    Gynecol Oncol; 2018 Jun; 149(3):491-497. PubMed ID: 29678360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.
    Lindell M; Sanner K; Wikström I; Wilander E
    BJOG; 2012 Jan; 119(2):245-8. PubMed ID: 22017806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Fujita M; Nagashima K; Shimazu M; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Hanaoka H; Shozu M; Tsuruoka N; Kasai T; Hata A
    Int J Cancer; 2024 Sep; 155(5):905-915. PubMed ID: 38648390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.
    Arrossi S; Paolino M; Laudi R; Gago J; Campanera A; Marín O; Falcón C; Serra V; Herrero R; Thouyaret L
    Lancet Glob Health; 2019 Jun; 7(6):e772-e783. PubMed ID: 31097279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.